The diverse European healthcare environment requires a specific approach to communications
The European market provides multiple challenges to the pharmaceutical industry, emerging biotechnology and medical technology firms who develop, launch and commercialize drugs and devices.
Deep and varied local and international insights, experience, capabilities and footprints are required for impactful healthcare communications in Europe because of the high diversity in local regulations, health systems, market dynamics, key stakeholders’ perceptions, as well as cultural nuances and languages.
A next-generation agency group that offers the perfect combination of global size and unprecedented capabilities with European and local expertise
As a part of Syneos Health, the only global biopharmaceutical accelerator integrating clinical development, real-world, late-stage and full commercialization, we serve the complex European healthcare market with tailored communications solutions for our clients’ clinical and commercial success.
Our key principles:
250+ European healthcare communications experts integrating their medical communications, PR, advertising and digital/multichannel expertise serve the 20 most important markets in Europe. Their unlimited access to Syneos Health global insights, therapeutic area expertise from mass to rare, and analytical assets allows us to develop unique, value-driven, scalable and measurable communications solutions tailored to Europe.
Our colleagues across Europe also bring diversity of thought — not just because of their French, German, British and other cultural codes — but as philosophers, six-sigma-level processors, and critical thinkers. Our team includes journalists, scientists, artists, data geeks and digital innovators — all sharing a desire to help our clients accelerate the benefits they can bring to doctors and patients.
Our capabilities include:
Medical Communications
Public Relations
Advertising
Through leveraging the power of storytelling in a user-friendly way, wrapped marketing has emerged as a viral global sensation, weaving its way into the fabric of brand promotion with unparalleled efficacy.
Read ArticleThis month policies aimed at lowering drug prices are back on the table. It’s noticeably less ambitious than earlier Democratic proposals, but still represents a historic shift in how drug pricing is approached in the United States.
Read ArticleAn update on the latest developments in Washington critical to Pharma leaders.
Read ArticleAlready have a RSS feed reader?
